A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (NCT07076121)

🧪 Interventions in This Study

• Navlimetostat (DRUG)
• Gemcitabine (DRUG)
• Nab-paclitaxel (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (269 Sites)

Showing the first 25 of 269 sites.

• Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
• Local Institution - 0365 — Tucson, Arizona
• Highlands Oncology Group — Springdale, Arkansas
• Scripps Green Hospital — La Jolla, California
• Local Institution - 0157 — San Francisco, California
• Baptist MD Anderson Cancer Center — Jacksonville, Florida
• Mayo Clinic in Florida — Jacksonville, Florida
• Winship Cancer Institute, Emory University — Atlanta, Georgia
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
• St. Luke's Cancer Institute: Boise — Boise, Idaho
• Local Institution - 0168 — Chicago, Illinois
• Local Institution - 0125 — Westwood, Kansas
• Local Institution - 0370 — Louisville, Kentucky
• Local Institution - 0371 — Baltimore, Maryland
• Johns Hopkins Hospital — Baltimore, Maryland
• Local Institution - 0120 — Boston, Massachusetts
• Brigitte Harris Cancer Pavilion — Detroit, Michigan
• The Cancer & Hematology Centers — Grand Rapids, Michigan
• Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
• University Of Nebraska Medical Center — Omaha, Nebraska
• Roswell Park Cancer Institute — Buffalo, New York
• Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
• Laura and Isaac Perlmutter Cancer Center at NYU Langone — Mineola, New York
• NYU Winthrop Hospital — Mineola, New York
• Icahn School of Medicine at Mount Sinai — New York, New York

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pancreatic Ductal Adenocarcinoma

• A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Rochester, New York
• Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) — Kansas City, Kansas
• Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer — Durham, North Carolina
• Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer — Washington D.C., District of Columbia
• A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma — Philadelphia, Pennsylvania
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma — Los Angeles, California

Explore by condition: All Pancreatic Ductal Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.